Role of cystatin C in urogenital malignancy

被引：11

作者：

Ding, Li ^{[1
]}

Liu, Zijie ^{[2
]}

Wang, Junqi ^{[1
]}

机构：

[1] Xuzhou Med Univ, Affiliated Hosp, Dept Urol, Xuzhou, Jiangsu, Peoples R China

[2] Nanjing Med Univ, Wuxi Peoples Hosp No 2, Dept Urol, Wuxi, Jiangsu, Peoples R China

来源：

FRONTIERS IN ENDOCRINOLOGY | 2022年 / 13卷

关键词：

urogenital malignancy; cystatin C; proteinase inhibitor; renal function; survival prediction; tumor progression; GLOMERULAR-FILTRATION-RATE; RENAL-FUNCTION; PROSTATE-CANCER; SERUM; EXPRESSION; IMPACT; CHEMOTHERAPY; INHIBITORS; CARCINOMA; MARKERS;

D O I：

10.3389/fendo.2022.1082871

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Urogenital malignancy accounts for one of the major causes of cancer-related deaths globally. Numerous studies have investigated novel molecular markers in the blood circulation, tumor tissue, or urine in order to assist in the clinical identification of tumors at early stages, predict the response of therapeutic strategies, and give accurate prognosis assessment. As an endogenous inhibitor of lysosomal cysteine proteinases, cystatin C plays an integral role in diverse processes. A substantial number of studies have indicated that it may be such a potential promising biomarker. Therefore, this review was intended to provide a detailed overview of the role of cystatin C in urogenital malignancy.

引用

页数：10

共 73 条

[1] Cystatins [J].

Abrahamson, M ;

Alvarez-Fernandez, M ;

Nathanson, CM .

PROTEASES AND THE REGULATION OF BIOLOGICAL PROCESSES, 2003, 70 :179-199

[2] STRUCTURE AND EXPRESSION OF THE HUMAN CYSTATIN-C GENE [J].

ABRAHAMSON, M ;

OLAFSSON, I ;

PALSDOTTIR, A ;

ULVSBACK, M ;

LUNDWALL, A ;

JENSSON, O ;

GRUBB, A .

BIOCHEMICAL JOURNAL, 1990, 268 (02) :287-294

[3] Cystatin C as a biomarker of chronic kidney disease: latest developments [J].

Benoit, Stefanie W. ;

Ciccia, Eileen A. ;

Devarajan, Prasad .

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2020, 20 (10) :1019-1026

[4] Cystatin C as a predictor factor in patients with renal cell carcinoma treated by everolimus [J].

Bodnar, Lubomir ;

Stec, Rafal ;

Dzierzanowska, Malgorzata ;

Synowiec, Agnieszka ;

Cierniak, Szczepan ;

Kade, Grzegorz ;

Szczylik, Cezary .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) :295-304

[5] Cystatin C as a Parameter of Glomerular Filtration Rate in Patients with Ovarian Cancer [J].

Bodnar, Lubomir ;

Wcislo, Gabriel Benedykt ;

Smoter, Marta ;

Gasowska-Bodnar, Agnieszka ;

Stec, Rafal ;

Synowiec, Agnieszka ;

Szczylik, Cezary .

KIDNEY & BLOOD PRESSURE RESEARCH, 2010, 33 (05) :360-367

[6]

Bodnar Lubomir, 2008, Pol Merkur Lekarski, V24, P307

[7]

Bölke E, 2011, STRAHLENTHER ONKOL, V187, P191, DOI 10.1007/s00066-010-2203-5

[8] Cystatins in cancer progression: More than just cathepsin inhibitors [J].

Breznik, Barbara ;

Mitrovic, Ana ;

Lah, Tamara T. ;

Kos, Janko .

BIOCHIMIE, 2019, 166 :233-250

[9] Comprehensive Characterization of the Vascular Effects of Cisplatin-Based Chemotherapy in Patients With Testicular Cancer [J].

Cameron, Alan C. ;

McMahon, Kelly ;

Hall, Mark ;

Neves, Karla B. ;

Rios, Francisco J. ;

Montezano, Augusto C. ;

Welsh, Paul ;

Waterston, Ashita ;

White, Jeff ;

Mark, Patrick B. ;

Touyz, Rhian M. ;

Lang, Ninian N. .

JACC: CARDIOONCOLOGY, 2020, 2 (03) :443-455

[10] Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease [J].

Carrero, Juan Jesus ;

Qureshi, Abdul Rashid ;

Nakashima, Ayumu ;

Arver, Stefan ;

Parini, Paolo ;

Lindholm, Bengt ;

Barany, Peter ;

Heimbuerger, Olof ;

Stenvinkel, Peter .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (01) :184-190

← 1 2 3 4 5 6 7 8 →